Two FDA dates carry the rare disease story

A launch story with sharp edges

Ultragenyx is in a narrow window. Its current drugs are real, but the bigger bull case rests on two FDA decisions in Q3 2026. DTX401, for glycogen storage disease type Ia, has an FDA action date of August 23, 2026. UX111, for Sanfilippo syndrome type A, has an FDA action date of September 19, 2026.

The good news is that the base business is not standing still. Q1 2026 revenue was $136 million, only slightly below $139 million a year earlier, and management blamed the drop mainly on the timing of Crysvita orders in Latin America. Evkeeza was the bright spot, with Q1 sales up 64% year over year.

The hard part is that this is still a high-risk biotech setup. UX111 already had FDA manufacturing pushback, and gene therapy launches can be slow even after approval. UX143, once a major late-stage asset, failed its Phase 3 primary endpoints in December 2025. Management now says it sees a basis to talk with regulators about a possible path forward, but investors do not yet know what that path is.

Finn's view is cautious because the company is not cheap on hope alone. The story can improve fast if the FDA says yes and launch demand is clear. It can also break if manufacturing questions return, if sales growth stays uneven, or if the 2027 profit plan depends too much on one-time items.

Small patient groups, high stakes

Ultragenyx finds, develops, and sells drugs for rare and ultra-rare diseases. These are illnesses with small patient groups, so each drug may serve a limited number of people. The payoff can still be large because approved rare disease drugs often have high prices and less direct competition.

Money comes from product sales of Crysvita, Dojolvi, Evkeeza, and Mepsevii, plus partner economics in some regions. Crysvita is the main revenue driver. Ultragenyx sells directly in some markets, including parts of Latin America, and also receives revenue from partners in other regions.

That model depends on focus. The company cut about 10% of its workforce in February 2026 and said it wants to reach profitability in 2027. That makes sense after the UX143 setback, but it also leaves less room for mistakes if the next gene therapy launches need more spending than planned.

The moat is not a factory or a mass-market brand. It is know-how: finding rare disease patients, running hard clinical trials, dealing with regulators, and building small but specialized sales teams. The weak point is that one failed trial or one FDA manufacturing issue can erase years of work.

What sells now, what could matter next

Q1 mix still leans on Crysvita

The mix below uses Q1 2026 revenue of $136 million. Crysvita, Dojolvi, and Evkeeza were disclosed separately, while the remaining share groups other product revenue, royalties, collaboration revenue, and smaller products such as Mepsevii.

What could go wrong

In one breath